Bispecific antibodies are next new thing in cancer immunotherapy - STAT

Bispecific antibodies are next new thing in cancer immunotherapy - STAT

STAT Plus: They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

By SHARON BEGLEY

AMGEN

Though signs point to bispecifics, like other immunotherapies, eliminating cancer in a small fraction of people, there are hints they could help many more.

READ MORE